

Supplemental Table 3.2c. Transition Probabilities for Eligible Cohort From 7 to 10 Months. Transition probabilities for the 8 potential states in the Markov model, as measured among all eligible individuals in the retrospective CD cohort.

Tx in Month 7	Tx in Month 10													
	Count	Row	Percent	95% CI	Total	lost to Follow-up	0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
0: no meds	4347	253	3120	795	66	33	8	22	7	3				
			76.2	19.4	1.6	0.8	0.2	0.5	0.2	0.1				
			74.9-77.5	18.2-20.7	1.2-2.0	0.6-1.1	0.1-0.4	0.3-0.8	0.1-0.4	0.0-0.2				
1: CS	2552	77	955	1395	21	15	2	32	10	4				
			38.6	56.4	0.8	0.6	0.1	1.3	0.4	0.2				
			36.7-40.5	54.4-58.3	0.5-1.3	0.3-1.0	0.0-0.3	0.9-1.8	0.2-0.7	0.0-0.4				
2: IFX	837	26	99	12	605	7	1	72	2	0				
			12.2	1.5	74.6	0.9	0.1	8.9	0.2	0.0				
			10.0-14.7	0.8-2.6	71.5-77.6	0.3-1.8	0.0-0.7	7.0-11.0	0.0-0.9	0.0-0.5				
3: ADA	332	4	32	6	2	247	2	3	30	0				
			9.8	1.8	0.6	75.3	0.6	0.9	9.1	0.0				
			6.8-13.5	0.7-3.9	0.1-2.2	70.3-79.9	0.1-2.2	0.2-2.6	6.3-12.8	0.0-1.1				
4: CTZ	68	3	9	2	0	1	42	0	0	7				
			13.8	3.1	0.0	1.5	64.6	0.0	0.0	10.8				
			6.5-24.7	0.4-10.7	0.0-5.5	0.0-8.3	51.8-76.1	0.0-5.5	0.0-5.5	4.4-20.9				
5: IFX + CS	175	6	17	8	82	1	0	56	0	2				
			10.1	4.7	48.5	0.6	0.0	33.1	0.0	1.2				
			6.0-15.6	2.1-9.1	40.8-56.3	0.0-3.3	0.0-2.2	26.1-40.8	0.0-2.2	0.1-4.2				
6: ADA + CS	55	1	6	7	2	22	0	0	13	0				
			11.1	13.0	3.7	40.7	0.0	0.0	24.1	0.0				
			4.2-22.6	5.4-24.9	0.5-12.7	27.6-55.0	0.0-6.6	0.0-6.6	13.5-37.6	0.0-6.6				
7: CTZ + CS	21	0	2	1	0	0	7	0	0	10				

Tx in Month 7	Tx in Month 10									
	Total	lost to Follow up	0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
Count			9.5	4.8	0.0	0.0	33.3	0.0	0.0	47.6
Row Percent										
95% CI			1.2-30.4	0.1-23.8	0.0-16.1	0.0-16.1	14.6-57.0	0.0-16.1	0.0-16.1	25.7-70.2

ADA = Adalimumab; CS = corticosteroids; CTZ = Certolizumab; IFX = Infliximab;
Tx = treatment. Gray shading denotes no change. Green shading denotes the
most common transition when other than no change.